Ivarmacitinib, a novel Janus kinase 1 inhibitor, may be considered a potential treatment for patients with moderate to severe ...

Sareum Holdings plc (LON:SAR – Get Free Report) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 29.92 ($0.38) ...

Trial data has suggested that upadacitinib, a JAK1-selective inhibitor, is more effective at treating RA than Humira. Some analysts predict sales could eventually reach $3 billion a year or more.

Patients with vitiligo are often told nothing can be done, but even severe disease is potentially treatable, a recent ...

Deuruxolitinib, a JAK1/JAK2 inhibitor, is FDA-approved for moderate to severe alopecia areata, marking a significant advancement in treatment options. The THRIVE-AA1 trial showed deuruxolitinib's ...

The company’s non-steroidal immunomodulator met the primary endpoint in a Phase II trial as a treatment for post-op ...

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...

Vanda Pharmaceuticals said the Food and Drug Administration has granted orphan-drug designation for VGT-1849A. VGT-1849A is a selective antisense oligonucleotide-based JAK2 inhibitor for the treatment ...

The global hand eczema treatment market is projected to experience robust growth, with a market value of USD 53 million in ...

Kepler Capital analyst Christophe dombu maintained a Sell rating on Galapagos (0JXZ – Research Report) on December 9 and set a price target of ...

SDC-1801 (autoimmune disease) SDC-1801, Sareum's TYK2/JAK1 inhibitor, continues to demonstrate promising therapeutic potential for a range of autoimmune diseases with a potential initial focus on ...